What is Automera?
Automera is a biotechnology company headquartered in Seattle, WA, specializing in the development of autophagy-targeting chimera small molecules, known as AUTACs. This innovative approach targets cellular degradation pathways, offering a new modality for treating diseases. The company's focus on AUTACs positions it at the forefront of precision medicine, aiming to unlock new therapeutic strategies for a range of conditions.
How much funding has Automera raised?
Automera has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2023): $16M with participation from Xora Innovation and EDBI
Key Investors in Automera
Xora Innovation
Xora Innovation is a venture capital firm that provides capital and support to deep tech entrepreneurs, with a focus on transforming essential industries. Their investments span Compute Communications, Climate Energy, and AI in Physical Industries, aiming to build the infrastructure of tomorrow.
EDBI
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991. They aim to create value and empower businesses to build sustainable legacies through strategic investments in fields like biotechnology and fintech.
What's next for Automera?
With this major strategic investment, Automera is poised for accelerated growth and the advancement of its AUTAC platform. The enterprise-level funding will likely support expanded research and development efforts, clinical trial progression, and the scaling of its operational capabilities. This backing from key investors signals strong confidence in Automera's scientific foundation and its potential to disrupt the biotechnology landscape.
See full Automera company page
